Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials

Breast cancers over-express the human epidermal growth factor receptor 2 (HER2) in about 15% of patients. This transmembrane tyrosine kinase receptor activates downstream signaling pathways and leads to proliferation of cancer cells. Trastuzumab, an anti-HER2 monoclonal antibody, improves outcome in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavaud, Pernelle, Andre, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243818/
https://www.ncbi.nlm.nih.gov/pubmed/25285786
http://dx.doi.org/10.1186/s12916-014-0132-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243818/
https://www.ncbi.nlm.nih.gov/pubmed/25285786
http://dx.doi.org/10.1186/s12916-014-0132-3

Ejemplares similares